Krystal Biotech Upgraded to Moderate Buy by Royal Bank of Canada

Krystal Biotech's (NASDAQ:KRYS) stock price has been given a boost by Royal Bank of Canada, which upgraded its rating from 'hold' to 'moderate buy'. This change in sentiment comes on top of other recent upgrades and positive predictions for the biotechnology company.

According to Zacks.com, several analysts have weighed in on Krystal Biotech's potential. Jefferies Financial Group reiterated a 'buy' rating with a price target of $474.00 per share, while Chardan Capital upgraded its rating to 'strong-buy'. TD Cowen and Citigroup also gave the company a 'buy' rating, with price targets of $403.00 and $386.00 per share respectively.

The consensus among analysts is that Krystal Biotech has an average rating of 'moderate buy', with a price target of $365.40 per share. This indicates that while there may be some variation in opinion about the company's future performance, most analysts are optimistic about its prospects.